Wells Fargo raised the firm’s price target on Ascendis Pharma (ASND) to $295 from $289 and keeps an Overweight rating on the shares. The firm thinks shares should trade up +5%-10% on the strong Q2. In the near-term, removal of the MBX overhang should further lift shares as U.S. Yorvipath launch revenues continue to ramp significantly – it’s not too late to own this launch, Wells adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma’s Promising Growth Trajectory: Buy Rating Affirmed Amid Strong Yorvipath Performance and Strategic Pipeline Developments
- Ascendis Pharma Reports Strong Q2 2025 Growth
- Ascendis Pharma: Strong Product Performance and Growth Potential Drive Buy Rating
- Ascendis Pharma Reports Increased Revenue but Sustained Losses in H1 2025
- Ascendis Pharma reports Q2 EPS (EUR 0.82) vs. (EUR 2.21) last year